Kura Oncology, Inc. (NASDAQ:KURA) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 35.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,425,960 shares of the company's stock after acquiring an additional 372,196 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.83% of Kura Oncology worth $12,419,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock worth $144,000 after purchasing an additional 1,750 shares during the period. Rhumbline Advisers increased its position in shares of Kura Oncology by 2.0% during the fourth quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock valued at $871,000 after acquiring an additional 1,923 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock worth $430,000 after acquiring an additional 2,076 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of Kura Oncology by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock worth $120,000 after purchasing an additional 2,285 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock valued at $7,997,000 after purchasing an additional 3,092 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages recently weighed in on KURA. UBS Group cut their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Barclays decreased their price target on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a research note on Monday, April 28th. Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. Finally, BTIG Research cut shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $23.89.

Kura Oncology Stock Performance

NASDAQ:KURA traded down $0.29 during trading hours on Tuesday, reaching $5.80. 1,005,383 shares of the company's stock were exchanged, compared to its average volume of 1,174,528. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average of $6.51 and a 200 day moving average of $9.01. The firm has a market capitalization of $502.14 million, a price-to-earnings ratio of -2.46 and a beta of 0.50. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. Research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.